Susquehanna International Group’s Iovance Biotherapeutics IOVA Stock Holding History

Susquehanna International Group’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.99M	Buy	1,992,300 +1,332,900	+202%	+$4.26M	﹤0.01%	3667
2025 Q4	$1.8M	Sell	659,400 -260,800	-28%	-$603K	﹤0.01%	5864
2025 Q3	$2M	Buy	920,200 +434,700	+90%	+$1.03M	﹤0.01%	5799
2025 Q2	$835K	Sell	485,500 -346,800	-42%	-$863K	﹤0.01%	7909
2025 Q1	$2.77M	Sell	832,300 -1,195,800	-59%	-$6.17M	﹤0.01%	4819
2024 Q4	$15M	Buy	2,028,100 +1,221,000	+151%	+$11.3M	﹤0.01%	2165
2024 Q3	$7.58M	Sell	807,100 -182,100	-18%	-$1.73M	﹤0.01%	2986
2024 Q2	$7.93M	Buy	989,200 +219,900	+29%	+$2.36M	﹤0.01%	2781
2024 Q1	$11.4M	Sell	769,300 -183,400	-19%	-$2.13M	﹤0.01%	2431
2023 Q4	$7.75M	Sell	952,700 -218,800	-19%	-$1.14M	﹤0.01%	3006
2023 Q3	$5.33M	Buy	1,171,500 +877,200	+298%	+$5.73M	﹤0.01%	3407
2023 Q2	$2.07M	Buy	294,300 +147,900	+101%	+$1.06M	﹤0.01%	5086
2023 Q1	$895K	Buy	146,400 +63,500	+77%	+$438K	﹤0.01%	7106
2022 Q4	$530K	Sell	82,900 -60,700	-42%	-$474K	﹤0.01%	7709
2022 Q3	$1.38M	Sell	143,600 -47,700	-25%	-$550K	﹤0.01%	5791
2022 Q2	$2.11M	Buy	191,300 +102,500	+115%	+$1.34M	﹤0.01%	4805
2022 Q1	$1.48M	Sell	88,800 -175,400	-66%	-$2.71M	﹤0.01%	6169
2021 Q4	$5.04M	Sell	264,200 -51,800	-16%	-$1.14M	﹤0.01%	3724
2021 Q3	$7.79M	Buy	316,000 +84,100	+36%	+$1.98M	﹤0.01%	3246
2021 Q2	$6.03M	Buy	231,900 +150,200	+184%	+$3.9M	﹤0.01%	3678
2021 Q1	$2.59M	Sell	81,700 -259,800	-76%	-$10.8M	﹤0.01%	5302
2020 Q4	$15.8M	Buy	341,500 +188,300	+123%	+$7.48M	﹤0.01%	1982
2020 Q3	$5.04M	Sell	153,200 -260,500	-63%	-$7.99M	﹤0.01%	3032
2020 Q2	$11.4M	Buy	413,700 +167,000	+68%	+$5.49M	﹤0.01%	2001
2020 Q1	$7.38M	Buy	246,700 +123,800	+101%	+$3.28M	﹤0.01%	2098
2019 Q4	$3.4M	Buy	122,900 +35,300	+40%	+$803K	﹤0.01%	3507
2019 Q3	$1.59M	Buy	87,600 +50,700	+137%	+$1.12M	﹤0.01%	4672
2019 Q2	$905K	Buy	36,900 +11,900	+48%	+$179K	﹤0.01%	5894
2019 Q1	$238K	Sell	25,000 -4,400	-15%	-$42.7K	﹤0.01%	7606
2018 Q4	$260K	Sell	29,400 -73,600	-71%	-$710K	﹤0.01%	7262
2018 Q3	$1.16M	Sell	103,000 -8,000	-7%	-$114K	﹤0.01%	4935
2018 Q2	$1.42M	Buy	111,000 +47,600	+75%	+$696K	﹤0.01%	4652
2018 Q1	$1.07M	Buy	63,400 +24,000	+61%	+$363K	﹤0.01%	5087
2017 Q4	$315K	Buy	39,400 +22,800	+137%	+$183K	﹤0.01%	7511
2017 Q3	$129K	Buy	+16,600	New	+$105K	﹤0.01%	8265
2017 Q2	–	Sell	-14,000	Closed	-$104K	–	9481
2017 Q1	$104K	Sell	14,000 -247,300	-95%	-$1.81M	﹤0.01%	8369
2016 Q4	$1.82M	Buy	261,300 +122,700	+89%	+$844K	﹤0.01%	4262
2016 Q3	$1.14M	Sell	138,600 -68,000	-33%	-$575K	﹤0.01%	4556
2016 Q2	$1.67M	Buy	206,600 +172,700	+509%	+$1.08M	﹤0.01%	3896
2016 Q1	$172K	Buy	33,900 +9,700	+40%	+$53.1K	﹤0.01%	8096
2015 Q4	$187K	Sell	24,200 -11,000	-31%	-$76.3K	﹤0.01%	8482
2015 Q3	$203K	Sell	35,200 -36,400	-51%	-$283K	﹤0.01%	8679
2015 Q2	$657K	Buy	+71,600	New	+$799K	﹤0.01%	7083

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Susquehanna International Group's IOVA Position: Q1 2026 in Review

Susquehanna International Group reduced its Iovance Biotherapeutics (IOVA) stake by 39% in Q1 2026, selling an estimated $6.24M and leaving 2,996,743 shares worth $10.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3040.

Susquehanna International Group first reported a position in IOVA in Q1 2015 and has held it in 35 quarters since. The position peaked at $26.9M in Q1 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Susquehanna International Group held 2,996,743 shares of Iovance Biotherapeutics worth $10.5M as of Q1 2026.
Susquehanna International Group sold 1,951,871 Iovance Biotherapeutics shares in Q1 2026, an estimated $6.24M.
Iovance Biotherapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3040 holding.
Susquehanna International Group first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 35 quarters since.
Susquehanna International Group's Iovance Biotherapeutics position peaked at $26.9M in Q1 2024.
285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.